Nektar Therapeutics 주식 (NASDAQ: NKTR)

에 대한 최신 뉴스 Nektar Therapeutics (NASDAQ:NKTR) 주식

NEKTAR THERAPEUTICS

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Image34

ACOR

MSFT

NKTR

SMRT

SWKS

주식 시장 용어 중 일부는 완전히 당황스럽게 만들 수 있지만, 동시에 시장에 대한 이해를 높여줍니다. 그 중 하나가 시가총액 또는 시가총액의 약자인 마켓캡입니다.

시가총액이란 무엇입니까?

<h3>Gainers</h3>
<ul>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 13.6% to $1.46 during Tuesday's after-market session. The company's market cap stands at $11.1 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock rose 11.54% to $1.74. The company's market cap stands at $73.0 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares rose 9.11% to $1.04. The company's market cap stands at $18.5 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares rose 6.62% to $0.74. The company's market cap stands at $32.9 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 6.62% to $1.12. The market value of their outstanding shares is at $5.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 6.29% to $26.0. The company's market cap stands at $118.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares declined by 11.5% to $1.16 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 10.35% to $0.61. The company's market cap stands at $10.3 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares declined by 10.31% to $12.71. The market value of their outstanding shares is at $84.0 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) stock declined by 8.55% to $2.25. The market value of their outstanding shares is at $77.2 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares declined by 8.09% to $1.25. The market value of their outstanding shares is at $19.0 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares decreased by 7.95% to $0.8. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CASI

CBUS

CTXR

FBRX

LIXT

NMTC

NSPR

ONMD

OTRK

XTLB

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 128.3% to $21.78 during Tuesday's regular session. The market value of their outstanding shares is at $118.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 106.64% to $0.7. The company's market cap stands at $10.3 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 71.71% to $9.41. The market value of their outstanding shares is at $15.7 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock increased by 32.85% to $16.74. The market value of their outstanding shares is at $260.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 29.29% to $0.71. The company's market cap stands at $10.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares rose 27.51% to $25.5. The company's market cap stands at $520.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 37.9% to $1.0 during Tuesday's regular session. The market value of their outstanding shares is at $19.4 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock decreased by 19.17% to $1.94. The company's market cap stands at $17.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 18.49% to $1.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares fell 12.09% to $3.94. The market value of their outstanding shares is at $85.2 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 11.72% to $0.44. The company's market cap stands at $8.0 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 11.6% to $0.23. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

AMRN

ERNA

EYEN

INDP

LIMN

NTHI

SNGX

TRIB

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 1% on Tuesday.
The Dow traded up 1.11% to 43,054.08 while the NASDAQ gained 1.45% to 19,916.04. The S&amp;P 500 also rose, gaining, 1.07% to 6,089.42.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, energy stocks fell by 1.2%.
Top Headline
The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares shot up 67% to $18.18 after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</li>
<li>Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) got a boost, surging 137% to $22.62. The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares were also up, gaining 109% to $0.7135 after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares dropped 14% to $6.36 after the company announced a proposed private offering of $250 million in new convertible senior notes.</li>
<li>Shares of Advance Auto Parts, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) were down 9% to $47.23. Goldman Sachs analyst Kate McShane downgraded Advance Auto Parts from Neutral to Sell and lowered the price target from $48 to $46.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) was down, falling 31% to $12.82 as the company announced a $1.2 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded down 5.7% to $64.60 while gold traded down 2% at $3,326.70.
Silver traded down 1.5% to $35.650 on Tuesday, while copper rose 0.2% to $4.8585.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.11%, while Spain's IBEX 35 Index surged 1.41%. London's FTSE 100 gained 0.01%, Germany's DAX 40 gained 1.60% and France's CAC 40 rose 1.04% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.14%, Hong Kong's Hang Seng Index gaining 2.06%, China's Shanghai Composite rising 1.15% and India's BSE Sensex rising 0.19%.
Economics
<ul class="wp-block-list">
<li>The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 3.4% year-over-year in April following a 4.1% gain in the previous month.</li>
<li>The FHFA house price index fell by 0.4% from the previous month in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ARRY

HUSA

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

HC Wainwright &amp; Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and raises the price target from $6.5 to $120.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $120

WIIM

Nektar Therapeutics shares are trading higher after the company announced data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.62% to 42,846.32 while the NASDAQ gained 1.03% to 19,832.45. The S&amp;P 500 also rose, gaining, 0.68% to 6,066.06.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Information technology shares jumped by 1.2% on Tuesday.
In trading on Tuesday, energy stocks fell by 1.4%.
Top Headline
TD Synnex Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) reported better-than-expected earnings for the second quarter on Tuesday.
The company posted quarterly earnings of $2.99 per share which beat the analyst consensus estimate of $2.72 per share. The company reported quarterly sales of $14.95 billion which beat the analyst consensus estimate of $14.32 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares shot up 155% to $27.83 after the company announced a $500 million convertible notes private placement for its BNB treasury strategy.</li>
<li>Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) got a boost, surging 95% to $18.65. The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares were also up, gaining 81% to $0.6162 after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares dropped 59% to $4.0750.</li>
<li>Shares of Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) were down 47% to $5.22.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) was down, falling 37% to $11.65 as the company announced a $1.2 million registered direct offering.</li>
</ul>
Commodities In commodity news, oil traded down 4% to $65.82 while gold traded down 2.2% at $3,320.70.
Silver traded down 1.5% to $35.630 on Tuesday, while copper rose 0.9% to $4.8940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, while Spain's IBEX 35 Index surged 1.6%. London's FTSE 100 gained 0.4%, Germany's DAX 40 gained 1.8% and France's CAC 40 rose 1.3% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.14%, Hong Kong's Hang Seng Index gaining 2.06%, China's Shanghai Composite rising 1.15% and India's BSE Sensex rising 0.19%.
Economics
<ul class="wp-block-list">
<li>The U.S. current account deficit increased by 44.3% to $450.2 billion in the first quarter versus a revised deficit of $312 billion in the fourth quarter and compared to market estimates of a $443.3 billion gap.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 3.4% year-over-year in April following a 4.1% gain in the previous month.</li>
<li>The FHFA house price index fell by 0.4% from the previous month in April.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Highest Performances Holdings Inc. - American Depository Shares

MAAS

UPXI

Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings

Nektar Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">from Benzinga Pro</a>.
The company released statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46070929/rezolve-ad-phase-2b-study-of-rezpegaldesleukin-meets-primary-and-key-secondary-endpoints-in-patien" rel="noreferrer noopener">investigational rezpegaldesleukin</a>.
The global Phase 2b study is being conducted in 393 patients with moderate-to-severe <a href="https://www.benzinga.com/general/health-care">atopic dermatitis</a>. Patients in the study received three under-the-skin shots of rezpegaldesleukin.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupix" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI) from baseline at week 16 for all three dose arms of rezpegaldesleukin versus placebo.
All three dose arms also achieved statistical significance at week 16 for the key secondary endpoints of EASI-75 (percent of patients who achieve ≥75% reduction in EASI from baseline), EASI-50 (percent of patients who achieve ≥50% reduction in EASI from baseline) and BSA (mean percent improvement in Body Surface Area score from baseline).
After 16 weeks, patients had a 53% to 61% improvement in symptoms. This was compared to a 31% improvement for the placebo group.
The q2w arms of rezpegaldesleukin (high and middle doses) achieved statistical significance at week 16 for the key secondary endpoints of vIGA-AD 0/1 (percent of patients achieving a score of 0 or 1 on the validated Investigator&#8217;s Global Assessment for Atopic Dermatitis with ≥ 2-point reduction&nbsp;from baseline) and Itch NRS (percent of patients with baseline ≥ 4 who experienced a ≥&nbsp;4-point reduction&nbsp;in the Itch Numerical Rating Score from baseline).
In addition, at week 16, the high dose of 24 µg/kg q2w achieved statistical significance on EASI-90 (percent of patients who achieve ≥ 90% reduction in EASI from baseline).
Across all three dose arms, translational blood biomarker data demonstrate robust on-target and dose-dependent pharmacological activity.
The safety profile for the 16-week induction period for rezpegaldesleukin was consistent with previously reported results.
In the pooled rezpegaldesleukin arms, TEAEs, excluding ISRs, were reported in 60.3% of patients and in 57.5% of placebo-treated patients.
There was no increased risk of conjunctivitis, oral ulcers, or infections, including oral herpes, in the rezpegaldesleukin arms.
Nektar plans to submit these REZOLVE-AD 16-week induction results for presentation at a medical conference later in 2025.
Price Action: NKTR stock is trading higher by 108.6% to $19.90 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46071029/mark-zuckerbergs-ai-dreams-hit-whatsapp-speed-bump-as-openai-perplexity-challenge-meta-on-its-own-turf-report" target="_blank" rel="noreferrer noopener">Mark Zuckerberg&#8217;s AI Dreams Hit WhatsApp Speed Bump As OpenAI, Perplexity Challenge Meta On Its Own Turf: Report</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

Nektar Therapeutics Shares Double On Promising Eczema Drug Data

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 172.2% to $25.97 during Tuesday's pre-market session. The company's market cap stands at $118.3 million. </li>
<li>InMed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock moved upwards by 88.53% to $4.62. The company's market cap stands at $2.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 53.21% to $0.84. The market value of their outstanding shares is at $10.5 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 47.43% to $1.05. The market value of their outstanding shares is at $11.5 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock rose 37.18% to $20.99. The market value of their outstanding shares is at $298.3 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 24.68% to $0.23. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 30.4% to $1.12 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares fell 19.35% to $0.4. The market value of their outstanding shares is at $8.0 million. </li>
<li>ViewBix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>) shares declined by 14.48% to $3.31. The company's market cap stands at $25.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 13.34% to $1.43. The market value of their outstanding shares is at $5.3 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock fell 11.39% to $1.09. The company's market cap stands at $19.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 11.05% to $0.21. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBIO

DHAI

IBIO

PSTV

VBIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nektar's Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Phase 2b REZOLVE-AD Trial For Atopic Dermatitis, Showing Efficacy And Safety

Trading Halt: Halted at 7:00:00 a.m. ET - Trading Halt: Halt News Pending

Shares of Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational <a href="https://www.benzinga.com/quote/NKTR">rezpegaldesleukin on June 24, 2025</a>.
Nektar Therapeutics shares jumped 30.3% to $12.44 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 55.8% to $1.11 in pre-market trading after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.</li>
<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) gained 27.7% to $0.2354 in pre-market trading after falling 5% on Monday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) gained 20.1% to $12.44 in pre-market trading.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 18.5% to $23.74 in pre-market trading after jumping over 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 17.2% to $0.3089 in pre-market trading after gaining 7% on Monday. Adial Pharmaceuticals recently announced the pricing of a $3.6 million offering.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) climbed 16.2% to $2.23 in pre-market trading.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 11.8% to $2.28 in pre-market trading. Rezolve AI shares gained around 6% on Monday after the company announced it will join the Russell 2000 and Russell 3000 indexes</li>
<li>WF Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) rose 9.2% to $7.10 in pre-market trading after dipping 6% on Monday.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) gained 5.8% to $8.36 in pre-market trading. Teladoc shares surged over 14% on Monday after Citron Research made comments about the company on social media.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares tumbled 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) shares fell 52.4% to $4.73 in pre-market trading after jumping over 268% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) declined 26.7% to $4.91 in pre-market trading after gaining 9% on Monday.</li>
<li>Indonesia Energy Corporation Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) dipped 25.4% to $3.64 in pre-market trading after falling around 4% on Monday.</li>
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) fell 23.8% to $1.76 in pre-market trading after jumping 30% on Monday.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) declined 22.1% to $1.16 in pre-market trading. Impact BioMedical shares jumped 345% on Monday after the company announced a limited merger and share exchange agreement with Dr Ashleys.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) fell 21.7% to $0.9160 in pre-market trading after jumping around 14% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) fell 8.2% to $4.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

DFDV

INDO

NINE

RBNE

RZLV

SRFM

TDOC

TMDE

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

U.S. futures were trading higher on Tuesday after a positive day of trading on Monday. Futures of major benchmark indices were trading higher.
President Donald Trump announced a &#8220;<a href="https://www.benzinga.com/news/25/06/46066239/dow-futures-jump-over-200-points-as-trump-announces-ceasefire-but-iran-says-no-agreement-crude-plunges">ceasefire</a>&#8221; in a Truth Social post, saying that "THE 12 DAY WAR" will be considered "ended." 
Despite this, the Foreign Minister of Iran, Syed Abbas Araghchi, refuted claims of a ceasefire, saying that there was "no agreement" for cessation of military operations, in a post on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As Iran has repeatedly made clear: Israel launched war on Iran, not the other way around. As of now, there is NO &quot;agreement&quot; on any ceasefire or cessation of military operations. However, provided that the Israeli regime stops its illegal aggression against the Iranian people no…
&mdash; Seyed Abbas Araghchi (@araghchi) <a href="https://twitter.com/araghchi/status/1937311435882922420?ref_src=twsrc%5Etfw">June 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The 10-year Treasury bond yielded 4.35% and the two-year bond was at 3.84%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 77.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.69%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.18%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Tuesday. The SPY was up 0.83% at $605.11, while the QQQ advanced 1.11% to $537.56, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Monday, U.S. stocks saw gains across most S&amp;P 500 sectors, with consumer discretionary, consumer staples, and real estate stocks leading the charge, though energy stocks diverged, ending the session in the red.
Economically, the S&amp;P Global US services PMI dropped to 53.1 in June from 53.7 the prior month, falling short of market expectations of 52.9. Meanwhile, the S&amp;P Global US manufacturing PMI held steady at 52 in June, matching the previous month's figure.
Shares of FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) rose approximately 3.5% on Monday after the company released its third-quarter results.
The Dow Jones index ended 375 points or 0.89% higher at 42,581.78, whereas the S&amp;P 500 index rose 0.96% to 6,025.17. Nasdaq Composite advanced 0.94% to 19,630.98, and the small-cap gauge, Russell 2000, gained 1.11% to end at 2,132.68.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.94%</td>
<td>19,630.98</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.96%</td>
<td>6,025.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.89%</td>
<td>42,581.78</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.11%</td>
<td>2,132.68</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Senior economist Jeremy Siegel expressed his opinions on the ongoing tensions as Trump announced a ceasefire.
&#8220;Geopolitics is a wildcard, but the U.S. is far less exposed than it was in the 1970s. Even a brief closure of the Strait of Hormuz would not derail domestic growth—shale capacity and strategic reserves mute the blow,&#8221; he said.
&#8220;I maintain that investors should stay overweight equities versus bonds,&#8221; he added, sayin that &#8220;don't just chase the AI enablers at high multiples to earnings; real margin expansion could very well accrue to users of AI—banks, industrial, consumer-staples, mid-cap firms that are learning where they can cut costs, increase output and improve margins.&#8221;
In its most recent note, BlackRock spotlighted the <a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-">defense sector as a top investment prospect</a>, fueled by escalating geopolitical fragmentation and a worldwide focus on national security.
As per BlackRock, the U.S. distinguishes itself through its extensive defense spending, which, according to SIPRI data, "spends more than double on defense than Europe."
Moreover, the U.S. hosts the world's most advanced defense and defense technology companies, acting as a vital provider of critical systems like air and missile defense for numerous countries.
Within the defense sector, BlackRock identifies substantial opportunities in defense tech. This expansive field includes not just artificial intelligence (AI) and software firms but also crucial IT services and hardware, such as semiconductors, that drive cutting-edge defense capabilities.
BlackRock observes that "growing geopolitical fragmentation and strategic competition in AI are reinforcing the global focus on national security and resilience – creating opportunities in defense." This highlights a targeted investment strategy in defense, where technological leadership and strong national security frameworks are increasingly critical.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s S&amp;P Case-Shiller home price index for 20 cities will be released by 9:00 a.m., and Cleveland Fed President Beth Hammack will speak at 9:15 a.m. ET.</li>
<li>June consumer confidence data will be out by 10:00 a.m., and the Fed Chairman Jerome Powell will testify to the House Financial Services Committee at 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) was up 0.58% in premarket on Tuesday as analysts expect it to report quarterly earnings of $2.72 per share on revenue of $14.32 billion, before the opening bell.</li>
<li>Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) rose 2.04% as analysts expect it to report quarterly earnings of 24 cents per share on revenue of $6.21 billion, before the opening bell.</li>
<li>Worthington Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) advanced 3.55% as analysts expect it to report quarterly earnings of 84 cents per share on revenue of $301.44 million, before the opening bell.</li>
<li>FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was 0.47% higher as analysts expect it to report quarterly earnings of $5.87 per share on revenue of $21.84 billion after the closing bell.</li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) was down 0.43% as it revised full-year 2025 housing revenue to be in the range of $6.3 billion to $6.5 billion, down from prior guidance of $6.6 billion to $7 billion.</li>
<li>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) dropped 1.31% as it commenced an underwritten public offering of $1 billion of its Class A common stock by a selling stockholder. It plans to concurrently repurchase $100 million of its common stock from the selling stockholder.</li>
<li>BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) jumped 1.62% as analysts expect it to report quarterly earnings of $0 per share on revenue of $112.19 million after the closing bell.</li>
<li>Ibio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) surged 44.58% after it announced a conference call scheduled for June 24 to discuss its obesity and cardiometabolic disease pipeline.</li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) zoomed 31.66% ahead of its investor call, where it plans to present top-line data from the 16-week induction period of its Phase 2b REZOLVE-AD clinical trial.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.40% to hover around $66.18 per barrel.
Gold Spot US Dollar fell 1.29% to hover around $3,325.68 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.30% at the 98.1240 level.
Asian markets ended higher on Tuesday as Australia's ASX 200, Japan's Nikkei 225, China&#8217;s CSI 300, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex indices advanced. European markets were also higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Photo courtesy: Shutterstock

CHWY

US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock moved upwards by 53.8% to $3.86 during Monday's after-market session. The company's market cap stands at $111.3 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock increased by 42.3% to $1.02. The market value of their outstanding shares is at $12.5 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 22.11% to $11.65. The market value of their outstanding shares is at $105.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock moved upwards by 14.96% to $3.15. The company's market cap stands at $4.2 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock rose 9.82% to $0.28. The market value of their outstanding shares is at $15.8 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 9.22% to $9.0. The market value of their outstanding shares is at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock fell 19.3% to $1.3 during Monday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock decreased by 6.88% to $0.28. The company's market cap stands at $1.1 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock declined by 6.87% to $1.9. The market value of their outstanding shares is at $75.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares declined by 5.87% to $0.43. The market value of their outstanding shares is at $18.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares decreased by 5.36% to $0.22. The company's market cap stands at $12.6 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock declined by 5.29% to $0.86. The company's market cap stands at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

CARM

CERO

CGTX

FEMY

HURA

NUWE

XBIO

12 Health Care Stocks Moving In Monday's After-Market Session

Nektar Therapeutics shares are trading higher after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin on June 24, 2025.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT.
The data will be provided in a morning press release and presented during the webcast.&nbsp;Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4454961-1&amp;h=3668145578&amp;u=http%3A%2F%2Fwww.nektar.com%2F&amp;a=www.nektar.com">www.nektar.com</a>. A replay of the webcast will be available for at least 30 days following the event.

Nektar Announces It Will Release Top-Line Data from 16-Week Induction Period In REZOLVE-AD Phase 2b Study of Rezpegaldesleukin On June 24, 2025

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

On June 6, 2025, Nektar Therapeutics (the "Company") filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Increase in Authorized Shares Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock, par value $0.0001 (the "Common Stock"), from 300,000,000 shares to 390,000,000 shares. The Increase in Authorized Shares Amendment was previously approved by the Company's stockholders at the Annual Meeting of Stockholders held on May 23, 2025 and became effective upon its filing.
&nbsp;
A copy of the Increase in Authorized Shares Amendment is filed as Exhibit 3.1 hereto and is incorporated herein by reference.
&nbsp;
On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Reverse Stock Split Amendment") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's Common Stock at a ratio of one-for-fifteen (the "Reverse Stock Split"). The Reverse Stock Split Amendment provides that the Reverse Stock Split will become effective as of 11:59 p.m. Eastern Time on June 8, 2025 (the "Effective Time"), at which time every fifteen shares of the Company's Common Stock issued and outstanding immediately prior to the Effective Time will be automatically combined into one share of Common Stock. No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, any fractional shares resulting from the Reverse Stock Split will be rounded up at the participant level with The Depository Trust Company, if such shares of Common Stock are held directly or rounded down to the nearest whole share of Common Stock, if such shares are subject to an award granted under the 2017 Amended and Restated Performance Incentive Plan.
&nbsp;
Trading of the Company's common stock on a split-adjusted basis will begin at market open on June 9, 2025 under the existing symbol "NKTR" and new CUSIP number 640268306. The Reverse Stock Split will not change the number of authorized shares of the Company's Common Stock, which will remain at 390,000,000 shares following effect of the Increase in Authorized Shares Amendment.
&nbsp;
A copy of the Reverse Stock Split Amendment is filed as Exhibit 3.2 hereto and is incorporated herein by reference.

Stock Split

Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 26.32 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $10.46 million which missed the analyst consensus estimate of $15.36 million by 31.89 percent. This is a 51.66 percent decrease over sales of $21.64 million the same period last year.

Earnings Misses

Nektar Therapeutics Q1 EPS $(0.24) Misses $(0.16) Estimate, Sales $10.46M Miss $15.36M Estimate

Press Releases

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

ALT5 Sigma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

MBX Biosciences

Omeros

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

scPharmaceuticals

SNDL

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

HC Wainwright & Co.

Jefferies

Oppenheimer

B. Riley Securities

Piper Sandler

by <a href="https://www.benzinga.com/money/author/shanthirexaline">SHANTHI REXALINE</a>



주식 시장 용어 중 일부는 완전히 당황스럽게 만들 수 있지만, 동시에 시장에 대한 이해를 높여줍니다. 그 중 하나가 시가총액 또는 시가총액의 약자인 마켓캡입니다.



<h2 class="wp-block-heading" id="how-market-capitalization-works">시가총액이 작동하는 방식</h2>



<a href="https://www.finra.org/investors/insights/market-cap#:~:text=Market%20capitalization%2C%20or%20market%20cap,by%20company%20officers%20and%20insiders." target="_blank" rel="noreferrer noopener">시가총액</a>은 기업의 가치를 주식의 발행 수와 현재 시장 가격을 고려하여 산정하는 지표입니다. 시가총액은 기업의 발행 주식 수와 주당 시장 가격의 곱으로 계산됩니다.



<ul>
<li>미발행 주식은 소매 및 기관 투자자, 회사 내부자 및 임원 등이 소유한 주식을 가리킵니다. 다시 말해, 미발행 주식은 기업 헌장에 인가된 주식으로 투자자에게 발행된 것을 의미합니다.</li>



<li>제한된 주식은 특정 조건을 충족하면 양도 가능합니다.</li>



<li>시가총액의 다른 측정 지표로 자유유동주 시가총액이 있습니다. 이는 일반 대중이 거래 가능한 자유롭거나 자유롭게 거래 가능한 주식만을 고려하여 시가총액을 계산하며, 내부자, 프로모터, 정부 등이 보유한 주식은 배제합니다.</li>
</ul>



<figure class="wp-block-embed is-type-rich is-provider-embed-handler wp-block-embed-embed-handler wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Market Cap &#x7C; by Wall Street Survivor" width="500" height="281" src="https://www.youtube.com/embed/_JNlku5xy9Q?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div></figure>



<h2 class="wp-block-heading" id="how-to-calculate-market-capitalization">시가총액 계산 방법</h2>



트위터 인코포레이티드(Social media platform Twitter Inc.) 주식은 2018년 화제를 모았으며, 여러 요인들이 상승 모멘텀을 촉진했습니다.



2018년 3월 31일 기준 트위터의 발행 주식 수는 752,037주였습니다. 2018년 6월 13일의 종가인 $44.07을 사용하여 트위터의 시가총액을 계산합니다. 트위터의 시가총액을 계산하려면 752,037 &#x2A; $44.07 = $33.14 십억 달러입니다. (2018년 6월 13일 기준)



<h2 class="wp-block-heading" id="factors-that-affect-market-cap">시가총액에 영향을 미치는 요소</h2>



시가총액은 발행 주식 수와 시장 가격 두 가지 요소의 곱으로 결정되기 때문에 이러한 요인들에 영향을 미치는 어떤 요인이든 시가총액에 영향을 줄 수 있습니다. 주가는 여러 가지 요인에 의해 결정됩니다:



<ul>
<li>수요와 공급</li>



<li>회사의 기본적인 강도</li>



<li>경쟁사의 성과</li>



<li>시장 민감성 또는 회사별 뉴스</li>



<li>기업 외적인 요인으로는 거시경제, 지정학 등이 있습니다.</li>
</ul>



발행 주식 수는 다음과 같은 요소에 의해 결정됩니다:



<ul>
<li>신규 주식 발행</li>



<li>주식 매입</li>
</ul>



주식에 대한 워런트의 행사가 시장 가격보다 낮은 가격에서 이루어지므로 이것은 회사의 시가총액에 영향을 줄 수 있습니다. 그러나 주식 분할 또는 배당금은 시가총액에 거의 영향을 미치지 않습니다. <a href="https://www.benzinga.com/money/how-do-dividends-work/">분할/배당금</a>으로 인해 발행 주식 수가 증가하지만 주식의 시장 가격이 감소함으로써 효과는 상쇄됩니다.



<h2 class="wp-block-heading" id="classifying-large-and-small-market-caps">크고 작은 시가총액 분류</h2>



시가총액을 기준으로 회사들은 나노캡, 마이크로캡, 소형캡, 중형캡, 대형캡 및 메가캡으로 분류될 수 있습니다. 각 범주의 기준은 다음과 같습니다:



<ul>
<li>나노캡: 시가총액이 5천만 달러 미만인 주식들입니다. 일반적으로 페니 주식으로, 과도한 이익을 얻기 위해 거대한 위험을 감수할 준비가 있는 거래자들에 의해 추구됩니다. 이러한 종목들은 일반적으로 대외 거래 시장에서 거래되며, 오버 더 카운터 게시판이나 핑크 시트에서 거래됩니다. 나노캡의 예로는 Aurora Solar Technologies, Inc.가 있습니다.</li>



<li>마이크로캡: 시가총액이 5천만 달러에서 3억 달러 사이인 주식들입니다. Stein Mart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NASDAQ">SMRT</a>)는 시가총액이 1억 3천 5백만 달러인 마이크로캡으로 뉴욕 증권 거래소에서 거래되고 있습니다.</li>



<li>소형캡: 시가총액이 3억 달러에서 20억 달러 사이인 주식들입니다. Acorda Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>)는 시가총액이 약 15억 달러인 소형캡 주식으로, 미국 나스닥 증권 거래소에서 거래되고 있습니다.</li>



<li>중형캡: 시가총액이 20억 달러에서 100억 달러 사이인 주식들입니다. Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>)는 약 99억 8천만 달러의 시가총액을 가진 생명공학 중형캡 기업으로, 거래되고 있습니다.</li>



<li>대형캡: 시가총액이 100억 달러에서 3천억 달러 사이인 주식들입니다. Apple의 공급업체인 Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)는 약 185억 달러의 시가총액을 가진 대형캡 기업입니다.</li>



<li>메가캡: 시가총액이 3천억 달러를 초과하는 주식들입니다. Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)는 메가캡의 한 예시입니다.</li>
</ul>



<h2 class="wp-block-heading" id="market-cap-equity-valuation-and-enterprise-value">시가총액: 주식 가치 평가와 기업 가치</h2>



시가총액은 기업을 가치화하는 한 가지 방법입니다. 이에 반해 자본 가치평가는 기업의 실제 순자산 가치를 제공하며 자산과 부채의 차이입니다. 그렇지 않으면 기업이 공정 가치에 매각되거나 청산될 때 주식을 보유한 투자자가 남게 될 금액을 나타냅니다.



시장 자본화와는 달리 자본 가치평가는 비교적 안정적입니다. 일반적으로 시가총액은 기업의 미래 수익 잠재력을 반영한 주식 가격이기 때문에 자본 가치평가보다 높습니다. 두 지표 모두 시장 자본화를 기업 가치평가로 나눈 가격 대 자산 가치 (P/B) 비율을 계산하는 데 사용됩니다.



P/B 비율이 1보다 크면 시장에서 기업이 고평가되었다는 것을 나타내고 그 반대도 마찬가지입니다. 한편, 기업 가치 (EV)는 시장 자본화 + 우선주의 시장 가치 + 소수 주주 이익 &#8211; 현금 및 투자로 계산됩니다.



대체로 할인된 현금 흐름 모델을 사용하여 모든 미래 현금 흐름의 현재 가치를 계산하여 EV를 계산할 수 있습니다.



<h2 class="wp-block-heading" id="pros-and-cons-of-using-market-capitalization">시가총액 사용의 장단점</h2>



시가총액에는 많은 이점이 있지만 몇 가지 단점도 있습니다. 시가총액의 장단점은 다음과 같습니다.



장점



<ul>
<li>기업을 가치화하는 가장 쉽고 널리 사용되는 방법으로 여겨집니다.</li>



<li>대형/초대형 기업은 시장 하락 시에도 안정된 수익을 창출한다고 인식되므로 비교적 안정적이고 안전한 기업을 식별할 수 있습니다.</li>



<li>다른 기업과의 상대적 크기를 이해할 수 있습니다.</li>



<li>지수를 구성하는 주식의 가중치를 결정하는 데 사용됩니다. 시가총액이 높은 주식은 지수에서 더 높은 가중치를 받습니다.</li>



<li>잘 균형 잡힌 포트폴리오를 구축하는 데 사용할 수 있습니다.</li>
</ul>



단점



<ul>
<li>이 척도는 기업의 부채 부담을 고려하지 않습니다. 따라서 시가총액을 사용하여 기업을 가치화하는 잠재적인 매수자는 부채 부담을 서비스하는 데 드는 비용을 고려하지 않을 수 있습니다.</li>



<li>배당금, 주식 분할 등과 같은 수익을 고려하지 않습니다.</li>
</ul>



<h2 class="wp-block-heading" id="stock-price-effects-your-growth-rate">주식 가격이 성장률에 영향을 미칩니다</h2>



시가총액은 잠재적인 매수자, 홍보자 또는 투자자가 무시하기 어려운 지표입니다. 그러나 기업의 전반적 가치를 파악하기 위해 이 정보를 다른 가치평가 방법과 함께 사용하는 것이 항상 좋습니다.

Comments

Nektar Therapeutics

뉴스

에 대한 최신 뉴스 Nektar Therapeutics (NASDAQ:NKTR) 주식

목요일, 4월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌